FDA ap­proves Apel­lis' reti­nal dis­ease drug as com­peti­tor ex­pects Au­gust de­ci­sion

The FDA ap­proved Apel­lis Phar­ma­ceu­ti­cals’ drug for ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion af­ter push­ing back the green light de­ci­sion by three months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER